MEDIZIN

DOC-CHECK LOGIN

The problem of evaluation of comprehensive care

 

From Prof. Dr. Ettore Beghi, Milan, Italy

 

Berlin (20. September 2008) – Comprehensive care in epilepsy, as with any chronic clinical condition, refers to the management of the disease and its complications and comorbidities aiming to obtain the maximal benefits in terms of satisfactory control of the symptoms in keeping with patients’ satisfaction and quality of life. Little is known about the impact of comprehensive care of epilepsy and this reflects into different patterns of care both at the primary level and in epilepsy clinics and other secondary and tertiary centres. There are several explanations for this: 1. The different characteristics and outcome of acute symptomatic seizures, isolated unprovoked seizures and epilepsy, which are frequently defined interchangeably; 2. The ill-defined association between epilepsy and several other clinical conditions, like depression (and other psychiatric disorders), headache and sleep disturbances; 3. The increasing number of drugs having different safety and tolerability profiles and effects on some comorbid conditions; 4. The differing perspectives of patients, caring physicians, and health care administrators regarding the cost-benefit ratio of the management of epilepsy; 5. An as yet lacking formal, evidence-based assessment of comprehensive care in epilepsy.

 

Acute symptomatic seizures (ie, seizures caused by immediate CNS insults), isolated unprovoked seizures and epilepsy (ie, repeated unprovoked seizures) represent clinical conditions having different severity and outcome and may require differing diagnostic and therapeutic management and a differing  approach at the primary (ie, general practitioner), secondary (ie, neurologist), and tertiary (ie, epileptologist) level. As well, the medical interventions may differ at the time of occurrence of a seizure and in the follow-up, when a full diagnostic and therapeutic work-up is required. Comorbidities require proper attention because a bidirectional cause-effect relationship may be present (Slides 1 & 2) and because ad-hoc treatments may be indicated. Epilepsy complications may be identified and managed to the benefit of the patient, in terms of satisfaction and quality of life, and to reduce disease-related direct and indirect costs. Second-generation antiepileptic drugs (AEDs) are currently available in increasing numbers. Although these compounds do not compete with classic AEDs in terms of efficacy, their pharmacokinetic and tolerability profiles are different and, in some occasions, better than those of the competitors. In addition, some of them have been found effective against symptoms of other comorbid disorders, like depression, headache and pain (Slide 3). Doctors’ main objective in the overall management of epilepsy is seizure control. In contrast, for the patient the focus of the disease management would be the use of drugs with minimal or no impact on daily living activities and overall quality of life. In this regard, the tolerability of a treatment may be more important than its efficacy. The health-care administrator looks for a cost-effective management with scarce impact on the available resources, in terms of minimal access to health care facilities and low monetary costs.

 

Surprisingly, the poverty of good quality reports does not provide sufficient high-level evidence in support of evidence-based standards of care in patients with epilepsy in a number of differing contexts: 1. The role of primary care and its interface with secondary care; 2. The role of physicians involved in the acute management of the disease and those required to complete the diagnostic and therapeutic work-up; 3. The cost-benefit ratio of epilepsy clinics and other tertiary centres compared to the other facilities dedicated to the care of epilepsy; 4. The impact of educational tools on improving the care of epilepsy by the different actors; 5. The integration of the patients’ views into the decision process.

 

In the light of the available evidence on the effectiveness of epilepsy services, more studies with robust methodology are required to support the best evidence-based recommendations and identify the most effective models of service provision for patients with epilepsy.

 

 

Beghi_1

 

Slide 1: Depression as a risk factor of epilepsy.

 

 

Beghi_2

 

Slide 2: Comorbidity of migraine and epilepsy.

 

 

Beghi_3

 

Slide 3: Effects of antiepileptic drugs on depression/mood, migraine and neuropathic pain.

 

 

 


 

Source: 8th European Congress on Epiteptology, Satellite Symposium: “Comprehensive Care of Epilepsy in Europe”, Berlin, 20. September 2008 (Medizin und PR Kommunikation).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…